DES and programmed surgery: reality or myth

Original title: Drug-Eluting Stents versus Bare Metal Stents Prior to Noncardiac Surgery. Reference: Sripal Bangalore, et al. Catheterization and Cardiovascular Intervention 2015;85:533-41

Drug eluting stents (DES) have proved beneficial compared to bare metal stents (BMS), but the need to program a surgical procedure after a percutaneous coronary intervention (PCI) has limited its use.

This study analyzed patients receiving PCI and non cardiac surgery (NCS) between April 2004 and September 2007. It included 8415 patients, 6538 (78%) receiving DES and 1877 BMS.

After propensity score matching was applied to adjust for differences, 5403 patients remained for final analysis, 3565 (66%) receiving DES and 1838 (34%) BMS. Primary end point was net clinical outcome at 30 days, a combination of death, infarction or bleeding.  

Population mean age was 69, 37% were diabetic, 20% had had previous revascualrization surgery, 23% previous PCI procedures and 43% had renal failure or were on dialysis.

In the DES cohort, the net clinical end point saw a reduction at 30 days, with longer time from PCI to NCS (p=0,02). The best outcome was obtained when surgery was performed after 90 days of PCI (event rate of 8.57, 7.53, 5.21, and 5.75% for 1-30, 31-90, 91-180 and 181-365 days, respectively, from PCI to NCS).

However, in the BMS cohort event rate was uniform and high, regardless PCI to NCS time (event rate of 8.20, 6.56, 8.05, and 8.82% for 1-30, 31-90, 91-180 and 181-365 days, respectively, from PCI to NCS. Finally, a marginal tendency to more bleeding was observed in the DES group. 

Conclusion

DES stents were not associated to more adverse events after a programmed NCS. Moreover, adverse events incidence was higher when NCS was performed 90 days after PCI, which suggests it is not necessary to wait 12 months after DES stenting to perform an NCS.

Editorial Comment

The need for surgery is relatively rare after PCI; even though the use of BMS is recommended, this retrospective analysis shows that the use of DES is a viable and safe alternative, especially after 90 days. However, we should collect more information and study groups that will benefit most before changing our clinical practices.

Courtesy of Dr. Carlos Fava
Interventional Cardiologist
Favaloro Foundation – Buenos Aires

Carlos Fava

More articles by this author

Polymer-Free vs. Biodegradable Polymer Stents: SORT OUT IX 5-Year Outcomes

In a constant strive to achieve life time management, interventional cardiologists focus on optimizing coronary scaffolds, which calls for the development of devices with...

Chronic Stent Recoil and Its Long-Term Effects

The evolution of stent technology—including new scaffold designs, thinner struts, and more biocompatible polymers—has brought about an emerging concern: the late loss of structural...

PROSPECT II Substudy: Relationship Between Different Levels of hs-CRP and Vulnerable Plaque Characteristics in Patients with NSTEMI

Inflammation plays a key role in the onset and progression of atherosclerosis and has been linked to a higher risk of cardiovascular events, regardless...

Aspirin vs. Clopidogrel Monotherapy After 1 Month of ACS: Subgroup Analysis Based on Bleeding Risk and MI Type

Current guidelines still recommend dual antiplatelet therapy (DAPT) for 12 months following percutaneous coronary intervention (PCI) as the standard treatment in patients with acute...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Heterotopic Treatment of the Tricuspid Valve

Tricuspid regurgitation (TR) has been associated to high morbimortality, mainly due to the development of cardiac failure, peripheral edema, ascites, kidney failure and cardiohepatic...

Polymer-Free vs. Biodegradable Polymer Stents: SORT OUT IX 5-Year Outcomes

In a constant strive to achieve life time management, interventional cardiologists focus on optimizing coronary scaffolds, which calls for the development of devices with...

Three-Year Outcomes of Mitral Valve-in-Valve Therapy with Balloon-Expandable Valves in the United States

Courtesy of Dr. Juan Manuel Pérez. Mitral Valve-in-Valve (MViV) implantation with balloon-expandable valves has become a solid alternative for patients with degenerated mitral bioprostheses. However,...